This website sets cookies which are used to offer a personalized experience on our website, generate statistics, and realize advertising or social network tracking. Find out more about our Privacy & Cookie policy and how to manage them on your browser. You can change your cookie settings at any time.

Out of public health concerns and given the current travel restrictions and lab closures worldwide because of COVID-19, the 27th International Symposium on Hepatitis C Virus and Related Viruses (HCV2020), scheduled to take place July 6 – 9, 2020 in Montreal, Canada has been postponed to July 6 - 9, 2021 and will now be delivered Virtually.

HCV2021 Program

VIRTUAL PLATFORM ACCESS

Click Here to access the HCV Virtual Platform.

Reach out to HCVregistration@mci-group.com for any assistance with logging in.


All times are in Eastern Daylight Time (EDT) / (GMT - 4:00)

*Program & Topics/Titles are Subject to Change 

Thursday, July 8, 2021

  • 10:00 11:30

    Session 7: Viral Life Cycle 2 (Translation, Assembly)

    Co-chairs: Thomas Pietschmann & Che Colpitts

    10:00 - 10:30 | Keynote Lecture 8: Unravelling miR-122 interactions with the HCV genome
                               Selena Sagan - McGill University, Quebec, Canada

    10:30 - 11:30 | Oral Presentations selected from Abstracts

    10:30 - 10:45 | N6-methyladenosine modification of HCV RNA genome regulates cap-independent IRES-mediated translation
                               Geon-Woo Kim, University of California, San Diego, United States

    10:45 - 11:00 | Microscopy study of apolipoprotein E trafficking to lipid droplets during HCV infection
                               Eva Herker, Philipps University Marburg, Germany

    11:00 - 11:15 | Role of hepatic apolipoproteins in HCV morphogenesis: a reassessment in primary human hepatocytes
                               Maxime Villaret, Université Paris Descartes, France

  • 11:30 12:00

    Break

  • 12:00 13:45

    Session 8: Antivirals: Challenges and New Frontiers

    Co-chairs: Daniel Lamarre & Georg Lauer

    12:00 - 12:30 | Plenary Lecture 6: Will HCV Reinfection be a Problem in High Risk Populations?
                               Julie Bruneau - CRCHUM, Montreal, QC, Canada

    12:30 - 13:00 | Keynote Lecture 9: Epigenetic Signatures Post HCV Cure by Direct-Acting Antivirals
                               Meital Gal-Tenamy - Bar-Ilan University, Israel

    13:00 - 13:45 | Oral Presentations selected from Abstracts 

    13:00 - 13:15 | N-phenylpyridine-3-carboxamide and 6-acetyl-1H-indazole inhibit the RNA replication step of dengue and Zika virus life cycles
                               Aïssatou Aïcha Sow, INRS-AFSB, Canada

    13:15 - 13:30 | Persistent perturbation of the circadian clock by chronic hepatitis C virus infection following cure with direct-acting antivirals
                               Frank Jühling, Université de Strasbourg, France

    13:30 - 13:45 | Re-treatment with direct-acting antivirals policy is needed to eliminate Hepatitis C among persons who inject drugs
                               Eric Tatara, Argonne National Laboratory, United States

  • 13:45 14:00

    Break

  • 14:00 16:00

    Session 9: Adaptive Immunity

    Co-chairs: Maike Hoffmann & Eui-Cheol Shin

    14:00 - 14:30 | Plenary Lecture 7: Friend and Foe: The complex interactions between dengue and Zika virus immune responses and epidemiology
                               Eva Harris - University of California, Berkely, USA

    14:30 - 15:00 | Keynote Lecture 10: Neutralizing Antibodies and Protective Immunity Against HCV
                               Justin Bailey - John Hopkins School of Medicine, Baltimore, MD

    15:00 - 16:00 | Oral Presentations selected from Abstracts  

    15:00 - 15:15 | Cellular metabolic profiles connected to the heterogeneity of exhausted T cells in Hepatitis B and Hepatitis C Virus infection
                               Frances Winkler, University Medical Center Freiburg, Germany

    15:15 - 15:30 | CD8 T cell Immunodominance in Acute HCV Infection and How It Drives Viral Mutation and Rebound
                               Bill G Bremer, Nationwide Children's Hospital, United States

    15:30 - 15:45 | B cell receptor CDR3 sequence sharing in spontaneous clearance of hepatitis C virus
                               Nicole E Skinner, Johns Hopkins, United States

    15:45 - 16:00 | Serum neutralizing activity declines rapidly, but memory B cells persist for decades after cure of chronic hepatitis C virus infection
                               Akira Nishio, National Institute of Diabetes and Digestive and Kidney Diseases, United States

  • 16:00 16:30

    Break

  • 16:30 18:30

    Poster Session II : Viral Life Cycle 1 & 2, Adaptive Immunity, Antivirals, Vaccines

    16:30 -17:15 |Poster Tour C: Adaptive immunity and antivirals
    Co-chairs: Mohamed S. Abdel-Hakeem & Angela Crawley

    Enriched plasma cell transcriptomic signatures and humoral responses during HCV reinfection and clearance
    Sabrina Mazouz, CRCHUM, Canada

    Spontaneous HCV-specific CD4+ T cell recovery and viral control after pregnancy is linked to a dominant T follicular phenotype
    Christopher Phelps, Nationwide Children's Hospital, United States

    In vitro adaptation and characterization of attenuated hypervariable region 1 swap chimeras of hepatitis C virus
    Christina Olesen, University of Copenhagen, Denmark

    The pivotal role of exosomal cargo in the immune response of chronic HCV patients after treatment with DAAs
    Eirini Karamichali, Hellenic Pasteur Institute, Greece

    17:15 -18:00 |Poster Tour D: Vaccines
    Co-chairs: Andrea Cox & Mansun Law

    3D Reconstruction of HCV Envelope Glycoproteins E1E2 Heterodimer by Electron Microscopic Analysis
    Tapan Kanai, Frederick National Laboratory For Cancer Research, National Cancer Institute(nci), United States

    Cross-neutralizing HCV antibody responses induced by a circularly permuted E1E2 nanoparticle vaccine
    Kwinten Sliepen, Amsterdam UMC, University of Amsterdam, Netherlands

    Structure-based design of an epitope-focused Hepatitis C virus vaccine
    Kumar Nagarathinam, Institute of Biochemistry, Germany

    Establishment of a VLP based Hepatitis C Virus Vaccine
    Joey McGregor, Burnet Institute, Australia

    Design and characterization of native-like secreted E1E2 with synthetic coiled coil scaffolds
    Johnathan Guest, University of Maryland, United States

    18:00 -18:30 |Poster Session Continued

  • 18:30 19:15

    Networking

  • 19:15 19:30

    Day Three Close